Rhythm Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alstrom syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders. It is also ... view company details
Royal Gold, Inc., together with its subsidiaries, acquires and manages precious metal streams, royalties, and related interests. It focuses on acquiring stream and royalty interests or to finance projects that are in production or in development stage in exchange for stream or royalty interests, which primarily consists of gold, silver, copper, nickel, zinc, lead, cobalt, and molybdenum. As of August 1, 2018, the company owned interests in 191 properties on 6 continents, including interests on 40 producing mines and 18 development stage projects. Its principal producing stream and royalty inte... view company details
SCYNEXIS, Inc., a drug development company, develops and commercializes anti-infectives to address unmet therapeutic needs. It is developing its lead product candidate, SCY-078, as a novel oral and intravenous drug for the treatment of various fungal infections, including serious and life-threatening invasive fungal infections. The company also develops SCY-078, which is in various Phase I studies for the oral and intravenous formulations, as well as has completed Phase II study as a step-down therapy in patients with invasive candidiasis and vulvovaginal candidiasis. It has research collabora... view company details
Synlogic, Inc. a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria. The company is also developing SYNB1891, an intratumorally administered syn... view company details
ServiceSource International, Inc. operates as a digital customer journey experience company. Its solutions include lead generation, inside sales, outsourced sales operations, customer onboarding, customer success management, cross-sell and upsell, warranty conversion, account-based marketing, and channel recruitment and enablement, as well as renewals management services, such as the sale of maintenance and support service contracts for the products used by its clients' end-users. The company also offers sales performance analysis, business case, pricing and contract structuring, data integrat... view company details
Foamix Pharmaceuticals Ltd., a late clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations for dermatological therapy in the United States, France, Denmark, and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline that has completed third pivotal Phase III clinical trial for the treatment of moderate-to-severe acne; and FMX103, which is in Phase III clinical trial for the treatment of moderate-to-severe papulopustular rosacea. The company's product pipeline includes FCD105 and FMX109 fo... view company details
Whiteboard Marketing LLC is a full-service sales and marketing consulting firm that provides a strategic partnership alliance with each client we serve. Our services include strategic marketing planning; marketing research internet/inbound marketing; social media campaigns; email strategy; SEO, PPC and SEM programs; media buying and placement; video production, website design, hosting and management; print collateral production and other services that drive sales and brand awareness. At Whiteboard Marketing, we utilize a calculated integration of all of these marketing initiatives to achieve R... view company details
Woods is a leading advocacy and service organization for people with exceptional challenges, disabilities and complex needs. We were founded a century ago by visionary Mollie Woods with two simple goals - to advance the quality of life and standard of care for individuals with disabilities. She gained international recognition for her groundbreaking work in helping children with exceptional needs experience the joy of achievement and lead fulfilling lives. Today, we've broadened her mission to serve people of all ages and levels of care with a unique model, The Exceptional Care Model, that dri... view company details
Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of various small molecule therapeutics to treat cystic fibrosis (CF) and other diseases caused by dysfunctional protein processing. The company's lead product candidates for the treatment of CF include PTI-801, a third generation cystic fibrosis transmembrane conductance regulator (CFTR) corrector agent; PTI-808, a CFTR potentiator; and PTI-428, a CFTR amplifier. It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize produc... view company details
For more than 45 years, Acts Retirement-Life Communities has met the retirement lifestyle and healthcare needs of older adults living in our communities. Our company began in 1971 with the vision of a church pastor and his congregation whose goal was to create an environment that offered seniors a rewarding lifestyle and high quality healthcare if ever needed. Today, Acts is the largest not-for-profit owner, operator and developer of continuing care retirement communities (CCRCs) in the United States. Our 26 communities currently serve more than 10,000 residents in nine states. Our vision for ... view company details
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, an ophthalmic solution, which is in Phase IIb clinical trial for the treatment of dry eye diseases, as well as Phase III clinical trial for the treatment of allergic conjunctivitis, noninfectious anterior uveitis, and Sjogren-Larsson syndrome. Its portfolio also consists of ADX-1612, a small molecule heat shock protein 90 (Hsp90) inhibitor for the treatment of lymphoproliferative inflammatory diseases; a... view company details
Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food a... view company details
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients with rare genetic diseases and cancer. The company's lead product candidate includes pegzilarginase, a recombinant human Arginase 1 enzyme, which is in early clinical development stage for the treatment of Arginase 1 deficiency, an autosomal recessive metabolic disease caused by a marked decrease in the activity of the native arginase 1 enzyme; and for treating Arginine dependent cancers. Its preclinical pipeline products comprise AEB4104, a recombi... view company details
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is APL-2 that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria diseases; and in Phase II clinical trials for the treatment of cold agglutinin and warm antibody autoimmune hemolytic anemia diseases, as well as in Phase II clinical trials to treat four types ... view company details
Aileron Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing a novel class of therapeutics in the United States. The company's lead product candidate is ALRN-6924, a stapled peptide, which is in Phase I clinical trial for the treatment of advanced solid tumors or lymphomas; Phase IIa clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and advanced myelodysplastic syndrome (MDS); and Phase IIb trial to treat AML/MDS in combination with cytosine arabinoside. It also devel... view company details
Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops cell and gene therapies for life-threatening rare genetic diseases. Its lead programs include EB-101, an autologous, gene-corrected cell therapy for recessive dystrophic epidermolysis bullosa; ABO-102, an adeno-associated virus-based gene therapy for Sanfilippo syndrome type A; and ABO-101 an AAV-based gene therapy for Sanfilippo syndrome type B. The company also develops ABO-202 and ABO-201, which are AAV-based gene therapies for the CLN1 and CLN3 forms of Batten disease; ABO-401 for the treatment of cystic fibrosi... view company details
Alimera Sciences, Inc., a pharmaceutical company, engages in the research, development, and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It focuses on diseases affecting the back of the eye or retina. The company offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness. Its ILUVIEN is inserted in the back of the patient's eye in a non-surgical procedure, which allows for a self-seal... view company details
Aevi Genomic Medicine, Inc., a clinical stage biopharmaceutical company, researches and develops novel therapies for pediatric onset and life-altering diseases in the United States. The company's lead product candidates include AEVI-001, a glutamatergic neuromodulator, which has completed Phase II/III SAGA trial for the treatment of a genetically-defined subset of adolescent attention deficit hyperactivity disorder patients who have genetic mutations that disrupt the mGluR network resulting in glutamate imbalance; and AEVI-002, an anti-LIGHT monoclonal antibody that is in Phase Ib clinical tri... view company details
VISION: Achieva envisions a community where all people with disabilities lead lives of personal significance. MISSION: ACHIEVA advocates for, empowers, and supports people with disabilities and their families throughout their lives. CORE VALUES: Respect: Value and celebrate everyone. Passion: Be dedicated to ACHIEVA's mission and vision. Ethics: Infuse integrity, quality and best practices in everything we do. Change: Embrace and drive innovation toward inclusive person-centered practices. Team: Inspire, challenge and support each other. STRATEGIC PRIORITIES: Person Centered: Create and nurtur... view company details
American Friends of the Hebrew University (AFHU) was founded in 1925 by the American business and philanthropist, Felix M. Warburg. A national, not-for-profit 501(c) 3 organization headquartered in New York City, AFHU raises awareness of and support for the Hebrew University of Jerusalem, Israel's research powerhouse and most comprehensive institution of higher learning. Through the philanthropic leadership of American Friends from coast to coast, AFHU helps the university to recruit and retain outstanding faculty; build teaching and research facilities; provide scholarships and fellowships; a... view company details